Physician profile
Sandra Gomez
NPI 1033556717
$1,733.19
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $719 · 2023: $45.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $362.23 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $163.25 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $159.60 | 2021 | |
| Abbott Laboratories | $137.80 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $85.28 | 2021-2022 | |
| Abbvie INC. | $78.97 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.05 | 2021 | |
| Lilly USA, LLC | $65.61 | 2022-2023 | Reyvow, Emgality |
| Janssen Pharmaceuticals, INC | $62.24 | 2021-2022 | |
| Emd Serono, INC. | $58.03 | 2022-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $54.80 | 2021-2022 | |
| Csl Behring | $46.84 | 2021-2022 | |
| Kyowa Kirin, INC. | $44.33 | 2021-2022 | |
| Ucb, INC. | $43.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $34.99 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $33.15 | 2021-2022 | |
| Genzyme Corporation | $30.74 | 2021-2022 | |
| Argenx US, INC. | $29.22 | 2022-2023 | Vyvgart |
| Jazz Pharmaceuticals INC. | $27.67 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $26.32 | 2021 | |
| W. L. Gore & Associates, INC. | $23.62 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.94 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.88 | 2021 | |
| Lundbeck LLC | $14.29 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.67 | 2022 | |
| Neurocrine Biosciences, INC. | $13.53 | 2021 | |
| Amgen INC. | $13.38 | 2022 | |
| Harmony Biosciences LLC | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.